Treatment of Polycythemia Vera in Patients Aged 60 or Older and/or with a History of Thrombosis
Polycythemia vera in patients aged 60 or older, or with a prior history of thrombosis, is classified as high-risk disease. This classification calls for an active, structured management approach aimed at reducing further complications and maintaining hematocrit within defined target thresholds.
Clinical Scenario
High-risk polycythemia vera: patients who are 60 years of age or older and/or have a history of thrombosis. This risk profile is the basis for the treatment intensity outlined in this protocol.
Treatment Approach (Partial Overview)
Management in this high-risk setting involves cardiovascular risk factor control combined with cytoreductive therapy, targeting hematocrit reduction as the primary measurable goal. The protocol defines specific agent options and thresholds for both male and female patients.
The complete regimen — agent selection, full sequencing, and all clinical targets — is available in the full protocol below.
References
- High Risk – Patients who have PV 60 years or older and/or have a history of thrombosis.
- Manage cardiovascular risk factors
- Cytoreductive therapy (medications to reduce the number of blood cells)
- Phlebotomy to keep hematocrit below 45 percent for males, or 42 percent for females
View source ↗